Do you want to read an article? Please log in or register.
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
Psoriatic Arthritis
Related content
Psoriatic Arthritis
Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase 3 Trial
Arthritis Rheumatol.
Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, Kricorian G, Chung JB
doi: 10.1002/art.40851.
Psoriatic Arthritis
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis
Arthritis Rheumatol.
Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS
doi: 10.1002/art.40391.
Rheumatoid Arthritis
Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study
Clin Rheumatol.
Gaubitz M, Göttl KH, Behmer O, Lippe R, Meng T, Löschmann PA
doi: 10.1007/s10067-017-3757-8.
EULAR ® 2019
Psoriatic Arthritis
Psoriatic Arthritis
Mease et al. 2019. A randomized, phase III, double-blind trial examining methotrexate and etanercept as monotherapy or in combination for treating psoriatic arthritis: a comparison of the composite measures used to evaluate disease activity. Oral presentation presented at: EULAR 2019 Congress; 12–15 June 2019; Madrid, Spain.
Psoriatic Arthritis
Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial
Arthritis Res Ther.
de Jong HMY, van Mens LJJ, Nurmohamed MT, Kok MR, van Kuijk AWR, Baeten DLP, van de Sande MGH
doi: 10.1186/s13075-019-1998-4.
Rheumatoid Arthritis
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
Ann Rheum Dis
Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landewé RB, Atsumi T, Burmester GR
doi: 10.1136/annrheumdis-2020-219213
COMMENTED
Psoriatic Arthritis
GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
★ 1
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
doi: 10.1136/annrheumdis-2019-216500.
Psoriatic ArthritisFurther Publications Rheumatology
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
Ann Rheum Dis
Lindström U, Di Giuseppe D, Delcoigne B, Glintborg B, Möller B, Ciurea A, Pombo-Suarez M, Sanchez-Piedra C, Eklund K, Relas H, Gudbjornsson B, Love TJ, Jones GT, Codreanu C, Ionescu R, Nekvindova L, Závada J, Atas N, Yolbas S, Fagerli KM, Michelsen B, Rotar Ž, Tomšič M, Iannone F, Santos MJ, Avila-Ribeiro P, Ørnbjerg LM, Østergaard M, Jacobsson LT, Askling J, Nissen MJ
doi: 10.1136/annrheumdis-2021-220097
Rheumatoid Arthritis
Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission on Combination Therapy: A Randomized, Double-Blind Trial
Arthritis Rheumatol
Curtis JR, Emery P, Karis E, Haraoui B, Bykerk V, Yen PK, Kricorian G, Chung JB
doi: 10.1002/art.41589